Skip to main content

FGFR Gene Alteration clinical trials at UCLA

3 in progress, 1 open to eligible people

Showing trials for
  • LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3

    open to eligible people ages 18 years and up

    The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

    Santa Monica, California and other locations

  • TT-00420 (Tinengotinib) in Cholangiocarcinoma

    Sorry, in progress, not accepting new patients

    This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.

    Santa Monica, California and other locations

  • TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

    Sorry, not accepting new patients

    The objective of the study is to provide access to TAS-120 to patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements.

    Santa Monica, California and other locations

Last updated: